AMIX — Autonomix Medical, Inc.
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: NASDAQ
- Employees: 5
- Website: https://autonomix.com
Latest SEC filings for AMIX
- EFFECT — 2026-09-16
- 424B3 — 2026-09-16
- 8-K — 2026-09-16
- 424B5 — 2026-09-11
- 424B5 — 2026-09-11
- S-3 — 2026-09-04
- S-3 — 2026-09-04
- 8-K — 2026-08-26
- 10-Q — 2026-08-13
- EFFECT — 2026-08-05
Latest AMIX news
- — 112 issued or pending patent applications make up Autonomix's worldwide portfolio. - Stock Titan (Stock Titan)
- — Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation (globenewswire.com)
- — Autonomix Medical, Inc. (AMIX) stock price, news, quote and history - Yahoo Finance UK (Yahoo Finance UK)
- — Autonomix Medical, Inc. (AMIX) Stock Price, News, Quote & History - Yahoo! Finance Canada (Yahoo! Finance Canada)
- — Autonomix receives FDA feedback on sensing platform pathway By Investing.com - Investing.com Canada (Investing.com Canada)
- — Autonomix receives FDA feedback on sensing platform pathway By Investing.com - Investing.com South Africa (Investing.com South Africa)
- — FDA feedback supports a U.S. clearance path for a sensor that detects faint body signals - Stock Titan (Stock Titan)
- — Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance (globenewswire.com)
Educational tool only — not investment advice.